Innovation of novel sustained release compression-coated tablets for lornoxicam: Formulation and in vitro investigations

Drug Development and Industrial Pharmacy

Volumn 36, Issue 3, 2010, Pages 337-349

  Hamza, Yassin El Said ^a   Aburahma, Mona Hassan ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Compression coated tablets; Lornoxicam; Polyvinylpyrrolidone K 30; Solid dispersion; Sustained release

Indexed keywords

GLYCEROL BEHENATE; LACTOSE; LORNOXICAM; POVIDONE;

ANALGESIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COATING; DRUG DETERMINATION; DRUG SOLUBILITY; GASTROINTESTINAL TRANSIT; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTESTINE FLUID; PH; PHYSICAL CHEMISTRY; STOMACH JUICE; SUSTAINED DRUG RELEASE; TABLET FORMULATION; X RAY DIFFRACTION;

EID: 77249156121     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903170768     Document Type: Article

References (46)

1. Maggi L, Machiste EO, Torre ML, Conte U. (1999). Formulation of biphasic release tablets containing slightly soluble drugs. Eur J Pharm Biopharm, 48:37-42.
2. Lopes CM, Sousa Lobo JM, Pinto JF, Costa PC. (2007). Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen. AAPS PharmSciTech, 8(3):E76.
3. Homdrum EM, Likar R, Nell G. (2006). Xefo® rapid: A novel effective tool for pain treatment. Eur Surg, 38:342-352
4. Kidd B, Frenzel W. (1996). A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol, 23:1605-1611
5. Rainer F, Klein G, Mayrhofer F. (1996). A prospective, multicentre, open-label, uncontrolled Phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain. Eur J Clin Res, 8:1-13.
6. Staunstrup H, Ovesen J, Larsen UT, Elbaek K, Larsen U, Kroner K. (1999). Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J Clin Pharmacol, 39:834-841
7. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. (2005). Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol, 59:14-17
8. Aabakken L, Osnes M, Frenzel W. (1996). Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther, 10:151-156
9. Kehlet H, Dahl JB. (1992). Are perioperative nonsteroidal antiinflammatory drugs ulcerogenic in the short term? Drugs, 44(Suppl. 5):38-41.
10. Skjodt NM, Davies NM. (1998). Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet, 34:421-428
11. Balfour JA, Fitton A, Barradell LB. (1996). Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs, 51:639-657
12. El-Badry M, Fathy M. (2006). Enhancement of the dissolution and permeation rates of meloxicam by formation of its freezedried solid dispersions in polyvinylpyrrolidone K-30. Drug Dev Ind Pharm, 32:141-150
13. Pan RN, Chen JH, Chen RR. (2000). Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems. Drug Dev Ind Pharm, 26:989-994
14. Shah J, Vasanti S, Anroop B, Vyas H. (2009). Enhancement of dissolution rate of Valdecoxib by solid dispersions technique with PVP K 30 & PEG 4000: Preparation and in vitro evaluation. J Incl Phenom Macrocyclic Chem, 63:69-75.
15. Thybo P, Pedersen BL, Hovgaard L, Holm R, Mullertz A. (2008). Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30. Pharm Dev Tech, 13:375-386
16. Patel RP, Patel MM. (2007). Physicochemical characterization and dissolution study of solid dispersions of lovastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30. Pharm Dev Tech, 12:21-33.
17. Damian F, Blaton N, Kinget R, Van den Mooter G. (2002). Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire® 44/14 and PVP K30. Int J Pharm, 24:87-98.
18. Thybo P, Kristensen J, Hovgaard L. (2007). Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions. Pharm Dev Tech, 12:43-53.
19. Özyazici M, Gökçe EH, Ertan G. (2006). Release and diffusional modeling of metronidazole lipid matrices. Eur J Pharm Biopharm, 63:331-339
20. Gu X, Fediuk DJ, Simons FE, Simons KJ. (2004). Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine. Drug Dev Ind Pharm, 30:1009-1017
21. Barthelemy P, Laforêt JP, Farah N, Joachim J. (1999). Compritol® 888 ATO: An innovative hot-melt coating agent for prolongedrelease drug formulations. Eur J Pharm Biopharm, 47:87-90.
22. Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol, 27:48-49
23. Liew CV, Chan LW, Ching AL, Heng PW. (2006). Evaluation of sodium alginate as drug release modifier in matrix tablets. Int J Pharm, 309:25-37.
24. Lin SY, Lin KH, Li MJ. (2004). Formulation design of double-layer in the outer shell of dry-coated tablet to modulate lag time and time-controlled dissolution function: Studies on micronized ethylcellulose for dosage form design (VII). AAPS J, 6(3):e17.
25. British Pharmacopoeia. (2007). British Pharmacopoeia Commission. London: HMSO (Electronic version).
26. Lopes CM, Sousa Lobo JM, Pinto JF, Costa P. (2006). Compressed mini-tablets as a biphasic delivery system. Int J Pharm, 323:93-1000.
27. O'Neill MJ, Smith A, Heckelman PE, Budavari S, eds. (2001). The Merck Index, 13th ed. Whitehouse Station, NJ: Merck & Co. Inc.
28. Abdelkader H, Abdallah OY, Salem HS. (2007). Comparison of the effect of tromethamine and polyvinylpyrrolidone on dissolution properties and analgesic effect of nimesulide. AAPS PharmSciTech, 8(3):E65.
29. Modi A, Tayade P. (2006). Enhancement of dissolution profile by solid dispersion (kneading) technique. AAPS PharmSciTech, 7(3):68.
30. Kalaiselvan R, Mohanta GP, Manna PK, Manavalan R. (2006). Studies on mechanism of enhanced dissolution of albendazole solid dispersions with crystalline carriers. Indian J Pharm Sci, 68:599-607.
31. Zheng X, Yang R, Tang X, Zheng L. (2007). Part I: Characterization of solid dispersions of nimodipine prepared by hot-melt extrusion. Drug Dev Ind Pharm, 33:791-802. (Pubitemid 47123802)
32. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. (2007). Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm, 66: 334-347
33. Nokhodchi A, Talari R, Valizadeh H, Jalali MB. (2007). An investigation on the solid dispersions of chlordiazepoxide. Int J Biomed Sci, 3:211-217
34. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. (1999). Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm, 181:143-151
35. Ambike AA, Mahadik KR, Paradkar A. (2004). Stability study of amorphous valdecoxib. Int J Pharm, 282:151-162
36. Prabhu S, Brocks DR, Betageri GV. (2001). Enhancement of dissolution of ethopropazine using solid dispersions prepared with phospholipids and/or polyethylene glycol. Drug Dev Ind Pharm, 27:413-418
37. Varma MM, Pandi JK. (2005). Dissolution, solubility, XRD, and DSC studies on flurbiprofen-nicotinamide solid dispersions. Drug Dev Ind Pharm, 31:417-423
38. Sekikawa H, Nakano M, Arita T. (1978). Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem Pharm Bull, 26:118-126
39. Ribeiro L, Ferreira DC, Veiga FJ. (2005). In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. J Control Release, 103:325-339
40. Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. (1984). A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int J Pharm, 21:167-177
41. Yonezawa Y, Ishida S, Sunanda H. (2001). Release from or through a wax matrix system. I. Basic release properties of the wax matrix system. Chem Pharm Bull, 49:1448-1451
42. Li FQ, Hu JH, Deng JX, Su H, Xu S, Liu JY. (2006). In vitro controlled release of sodium ferulate from Compritol 888 ATObased matrix tablets. Int J Pharm, 324:152-157
43. El-Malah Y, Nazzal S, Khanfar NM. (2006). D-optimal mixture design: Optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms. Drug Dev Ind Pharm, 32:1207-1218
44. Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC, Takayama K. (2004). Once-daily propranolol extended-release tablet dosage form: Formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm, 58:607-614
45. Kranz H, Wagner T. (2006). Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations. Eur J Pharm Biopharm, 62:70-76
46. Cohen JL, Hubert BB, Rhodes CT. (1990). The development of USP dissolution and drug release standards. Pharm Res, 7: 983-987